IL6R and congenital rubella syndrome: Therefore, theoretically, the dramatic efficacy of tocilizumab in severely ill patients with CRS induced by CAR-T is mediated through suppression of the systemic activation of the trans-signaling pathway induced by the IL-6/sIL-6R complex.